Key result
Diltiazem added in vitro at 0.1 microgram/ml produced complete inhibition of AA-PAF synergistic platelet aggregation in post-aspirin treatment platelets from healthy volunteers.
Why the study?
Does diltiazem potentiate the inhibitory effect of aspirin on platelet aggregation in healthy volunteers?
Population
Platelet-rich plasma from 7 healthy volunteers
Comparison
Diltiazem added in vitro after in vivo aspirin… vs Platelet aggregation before diltiazem addition…
Design
Preclinical
Follow-up
7 to 10 days
Authors
Loading...
May support diltiazem-aspirin synergy for antiplatelet effects; hypothesis-generating in vitro data leave clinical benefit open.
Does diltiazem potentiate the inhibitory effect of aspirin on platelet aggregation in healthy volunteers?
Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation in vitro, suggesting a potential clinical benefit of combining low-dose aspirin and diltiazem for cardiovascular prophylaxis.
Altman et al. (1988) studied Healthy volunteers (n=7). Diltiazem and Aspirin vs. Aspirin alone / Baseline was evaluated on AA-PAF-induced platelet aggregation. Diltiazem added in vitro at 0.1 microgram/ml produced complete inhibition of AA-PAF synergistic platelet aggregation in post-aspirin treatment platelets from healthy volunteers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: